Edwards Lifesciences Corporation income statement & cash flow
In the fiscal year ended Dec 31, 2025, Edwards Lifesciences Corporation reported net income of $1.07B on revenue of $6.07B. Operating cash flow was $1.60B and capital expenditures were $260.20M, leaving $1.33B of free cash flow (operating cash flow minus capital expenditures).
Income statement and cash flow summary
| Fiscal year ended | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.96B | $3.44B | $3.72B | $4.35B | $4.39B | $5.23B | $4.46B | $5.01B | $5.44B | $6.07B |
| Gross profit | $2.17B | $2.56B | $2.78B | $3.23B | $3.31B | $3.98B | $3.74B | $4.03B | $4.32B | $4.73B |
| Operating income | $751.20M | $1.09B | $748.20M | $1.15B | $897.60M | $1.69B | $1.50B | $1.31B | $1.38B | $1.26B |
| Net income | $569.50M | $583.60M | $722.20M | $1.05B | $823.40M | $1.50B | $1.52B | $1.40B | $4.17B | $1.07B |
| Diluted EPS | $2.61 | $2.70 | $1.13 | $1.64 | $1.30 | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 |
| Operating cash flow | $704.40M | $1.00B | $926.70M | $1.18B | $1.05B | $1.73B | $1.22B | $895.80M | $542.30M | $1.60B |
| Capital expenditures | $176.10M | $168.10M | $238.70M | $254.40M | $407.00M | $325.80M | $244.60M | $253.00M | $252.40M | $260.20M |
| Reported in | 10-K 2019 | 10-K 2020 | 10-K 2021 | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 | 10-K 2026 |
Margins
Each figure divided by revenue for the same fiscal year.
| Fiscal year ended | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| Dec 2025 | 78.0% | 20.8% | 17.7% |
| Dec 2024 | 79.5% | 25.3% | 76.7% |
| Dec 2023 | 80.5% | 26.1% | 28.0% |
| Dec 2022 | 83.8% | 33.6% | 34.1% |
| Dec 2021 | 76.1% | 32.3% | 28.7% |
Source: SEC EDGAR XBRL company facts for CIK 1099800 (raw data). Most recent filing in this dataset: 10-Q filed Aug 4, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.